Lokelma costs roughly $28 per packet at wholesale, which translates to several hundred dollars a month for most patients on a maintenance dose. The price reflects a combination of factors: a $2.7 billion acquisition deal, a complex manufacturing process, patent protection lasting until 2035, and a clinical profile that positions it above older, cheaper alternatives.
What Lokelma Actually Costs
The current wholesale acquisition cost for Lokelma is about $28.36 per individual packet. Most patients take a 5g or 10g dose daily during the initial correction phase, then shift to a maintenance dose taken every other day or as needed. Depending on your prescribed regimen, a month of treatment can easily run $400 to $850 or more before insurance. That’s a steep price for a powder you mix with water, and it’s natural to wonder what’s behind it.
AstraZeneca Paid $2.7 Billion for the Drug
Lokelma didn’t originate inside AstraZeneca. A smaller company called ZS Pharma developed the compound, and in 2015, AstraZeneca acquired ZS Pharma for approximately $2.7 billion in an all-cash deal, paying $90 per share. That acquisition price gets baked into the drug’s commercial pricing. Pharmaceutical companies expect to recoup these investments over the life of a drug’s patent, and with a relatively narrow patient population (people with chronically elevated potassium levels), the per-patient cost has to be high enough to justify that upfront spend.
It’s Harder to Make Than It Looks
Lokelma isn’t a simple chemical pill. Its active ingredient is an inorganic crystalline compound, a three-dimensional lattice of zirconium and silicon atoms connected by oxygen bridges. The structure has to be precisely right: the pores in the crystal measure about 3 angstroms across, almost exactly matching the size of a potassium ion. That’s what gives the drug its selectivity.
Manufacturing this crystal is demanding. According to regulatory documents from Australia’s Therapeutic Goods Administration, the process requires tight control over the order raw materials are added, reaction and crystallization temperatures, mixing speeds and times, and the number of rinses. Two unwanted crystalline phases can form during production. These alternate structures also exchange ions, but they’re far less selective for potassium. X-ray diffraction testing is used at multiple stages to confirm the correct crystal formed and to detect contamination from those less useful phases. This level of quality control adds cost that a generic tablet manufacturer wouldn’t face.
It Works Faster and More Precisely Than Alternatives
For decades, the go-to treatment for high potassium was sodium polystyrene sulfonate (often known by the brand name Kayexalate), a resin that’s been around since the 1950s and costs very little. But that older drug is a blunt instrument. It grabs potassium, sure, but it also strips out calcium and magnesium, sometimes causing dangerous imbalances. Its selectivity for potassium is actually lower than its affinity for calcium and magnesium.
Lokelma is over 25 times more selective for potassium than for calcium or magnesium. Its exchange capacity for those minerals is so low it can’t even be reliably measured. That precision matters for patients who are already medically fragile, particularly those with kidney disease or heart failure who can’t afford to lose calcium or magnesium on top of everything else.
Speed is the other differentiator. Lokelma begins lowering potassium within one to six hours, with measurable reductions seen as early as one hour after a dose. Patiromer (brand name Veltassa), its main branded competitor, takes 7 to 48 hours to kick in and carries a specific warning against use in emergencies. In a sub-analysis of patients with severely elevated potassium (levels between 6.1 and 7.2), a single 10g dose of Lokelma reduced levels by 0.4 milliequivalents per liter within the first hour. That fast onset lets it serve double duty for both acute correction and long-term maintenance, which older drugs and even its main competitor can’t match.
No Generic Competition Until 2035
Lokelma’s last qualifying patent doesn’t expire until October 14, 2035. Five companies have filed applications to make generic versions, but none can launch until patent exclusivity ends or they successfully challenge the patents in court. Until then, AstraZeneca faces no price pressure from generic competitors, which is the single biggest reason the cost stays high. Once generics do enter the market, prices typically drop 80% or more within a few years.
The Cost Argument AstraZeneca Makes
From a health economics perspective, the drug’s price is partly justified by what it prevents. Hyperkalemia that isn’t managed at home can lead to emergency department visits and hospitalizations. While U.S.-specific hospitalization cost data varies, the pattern is consistent across studies: a single hospital admission for a potassium crisis in a patient with kidney disease or heart failure costs thousands of dollars, and severe episodes requiring intensive management cost far more. Keeping potassium controlled with a daily outpatient medication avoids those acute costs, and that’s the argument insurers weigh when deciding whether to cover Lokelma.
That said, the cost-effectiveness argument only holds if you’re comparing Lokelma to no treatment or to emergency care. For patients whose potassium is only mildly elevated, dietary changes or dose adjustments to other medications may be sufficient, and the economics look very different.
How to Lower Your Out-of-Pocket Cost
AstraZeneca runs a patient assistance program called AZ&Me that provides Lokelma at no cost to eligible patients. To qualify, you must be a U.S. resident, have no commercial or government insurance (with limited exceptions for Medicare beneficiaries who aren’t enrolled in the Extra Help/Low-Income Subsidy program), and have an annual adjusted gross income at or below 300% of the federal poverty level. If you’ve recently lost a job, lost insurance coverage, or experienced a significant change in income or household size, you may qualify even if your previous income was too high.
For patients with commercial insurance, AstraZeneca also offers copay assistance cards that reduce out-of-pocket costs, though specific savings amounts vary. Your prescribing doctor’s office or a specialty pharmacy can usually help you navigate these options. If you have Medicare Part D, the coverage gap (or “donut hole”) can make costs spike mid-year, so it’s worth asking your plan about tier placement and any preferred alternatives before filling the prescription.